gene

LIF

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about LIF: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

128Connections
30Hypotheses
0Analyses
50Outgoing
35Incoming
12Experiments
0Debates

Summary

LIF is a gene implicated in neurodegeneration research. Key relationships include: activates, inhibits, therapeutic target. Associated with Autoimmune, Cancer, Carcinoma. Connected to 58 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info
Gene SymbolLIF
Full NameLeukemia Inhibitory Factor
AliasesPage for LIF Receptor Protein
Chromosome5p13.1
FunctionThe LIF gene encodes a 202-amino acid secreted glycoprotein that acts as a multifunctional cytokine:
Molecular Weight190 kDa
Amino Acids202 aa
Exons20
PathwaysMAPK, PI3K
UniProt IDP15018
NCBI Gene ID3977
Ensembl IDENSG00000128342
OMIM159446
GeneCardsLIF
Human Protein AtlasLIF
Associated Diseasesmultiple sclerosis
InteractionsActin, AND, App, ASTROCYTE, ASTROCYTES, BDNF
KG Connections128 knowledge graph edges
DatabasesGeneCardsHPASTRING
🔮 Predicted Structure: LIF — AlphaFold P15018 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (4)

Knowledge base pages for this entity

Canonical Page

LIF — Leukemia Inhibitory Factor

gene · 1058 words

LIF Receptor Protein - Leukemia Inhibitory Factor Receptor

protein · 2026 words

LIF Protein — Leukemia Inhibitory Factor

protein · 786 words

LIFR - Leukemia Inhibitory Factor Receptor

gene · 749 words

Pathway Diagram

graph TD
    LIF["LIF"]
    LIFR["LIFR"]
    LIF -->|"binds"| LIFR
    neurite_damage(["neurite damage"])
    LIF -->|"protects against"| neurite_damage
    Cancer{"Cancer"}
    LIF -->|"inhibits"| Cancer
    Leukemia{"Leukemia"}
    LIF -->|"inhibits"| Leukemia
    Ms{"Ms"}
    LIF -->|"activates"| Ms
    Tumor{"Tumor"}
    LIF -->|"activates"| Tumor
    LIF -->|"activates"| Leukemia
    Carcinoma{"Carcinoma"}
    LIF -->|"activates"| Carcinoma
    LIF -->|"activates"| Cancer
    LIF -->|"therapeutic target"| Tumor
    EGFR["EGFR"]
    LIF -->|"activates"| EGFR
    Epigenetic(["Epigenetic"])
    LIF -->|"inhibits"| Epigenetic
    JAK_STAT(["JAK-STAT"])
    JAK_STAT -->|"activates"| LIF
    EGFR -->|"activates"| LIF
    GENES["GENES"]
    GENES -->|"activates"| LIF
    DNA["DNA"]
    DNA -->|"activates"| LIF
    STAT3["STAT3"]
    STAT3 -->|"activates"| LIF
    LIFR -->|"expressed in"| LIF
    GFAP["GFAP"]
    GFAP -->|"expressed in"| LIF
    SOX2["SOX2"]
    SOX2 -->|"activates"| LIF
    LIFR -->|"activates"| LIF
    AND["AND"]
    AND -->|"inhibits"| LIF
    CANCER["CANCER"]
    CANCER -->|"inhibits"| LIF
    HIPPO["HIPPO"]
    HIPPO -->|"activates"| LIF
    style LIF fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (93)

TargetRelationTypeStr
Tumoractivatesdisease0.75
Leukemiaactivatesdisease0.75
Canceractivatesdisease0.75
neurite damageprotects_againstprocess0.70
CYTOKINESinhibitsgene0.70

Incoming (35)

SourceRelationTypeStr
JAK-STATactivatespathway0.70
HIPPOactivatesgene0.60
CYTOKINESinhibitsgene0.60
INFLAMMATIONtherapeutic_targetgene0.60
ANDtherapeutic_targetgene0.60

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
SASP-Mediated Complement Cascade Amplification 0.910 neurodegeneration Senolytic therapy for age-related neurod
Sequential Iron Chelation (Deferoxamine) and GPX4 Restoratio 0.838 neurodegeneration View
Targeting SASP-Complement Amplification Through HIF-1α Downs 0.793 neurodegeneration What molecular mechanism causes VCP muta
G2019S primarily raises baseline LRRK2 kinase activity rathe 0.790 neurodegeneration Do pathogenic LRRK2 mutations amplify vo
LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Sub 0.776 Alzheimer's Disease Cell type vulnerability in Alzheimers Di
LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vul 0.770 Alzheimer's Disease Cell type vulnerability in Alzheimers Di
PARP1-NAD+-AIF bioenergetic collapse drives a self-amplifyin 0.760 neurodegeneration What mechanisms drive the self-amplifyin
Selective blockade of classical-pathway activation downstrea 0.750 neurodegeneration Does C1q function differ based on subcel
Iron-driven lipid peroxidation and GPX4 failure create a fer 0.750 neurodegeneration What mechanisms drive the self-amplifyin
Complement-SASP Amplification Cascade as Mechanistic Link 0.741 neurodegeneration Why have anti-Aβ clinical trials failed
Mutant-dependent amplification is context-dependent and stro 0.740 neurodegeneration Do pathogenic LRRK2 mutations amplify vo
TBK1 Loss-of-Function Amplifies C1q-Mediated Synapse Elimina 0.724 neurodegeneration How do the seven novel ALS genes functio
Microglial IFN-β Priming of Motor Neuron cGAS/STING Amplific 0.720 neurodegeneration What determines the specificity of TDP-4
Dual-Circuit Tau Vulnerability Cascade with Glial-Mediated A 0.696 neuroscience Circuit-level neural dynamics in neurode
Drp1-S616 Phosphorylation Fission Priming Enables t-Bid-Driv 0.693 neurodegeneration What upstream mechanisms cause TDP-43 to
Glial Neuroinflammatory Amplification by TDP-43 Pathology 0.680 neurodegeneration What mechanisms underlie TDP-43's contri
LPS-primed microglial trained immunity establishes persisten 0.670 neurodegeneration Synaptic pruning by microglia in neurode
Heat Shock Protein 70 Disaggregase Amplification 0.668 neurodegeneration TDP-43 phase separation therapeutics for
TREM2 Activation as an Amplification Node for R136S Protecti 0.657 neurodegeneration What molecular mechanisms underlie the d
TREM2 Antagonism in Late-Stage Tauopathy — Reducing Neuroinf 0.628 Alzheimer's disease TREM2 agonism vs antagonism in DAM micro
CaMKII-Dependent Synaptic Circuit Amplification 0.611 neuroscience Circuit-level neural dynamics in neurode
Myelin Breakdown-Amyloid Interaction Amplifies Cortical Agin 0.600 Alzheimer disease Allen Mouse Brain Aging Atlas: cross-age
NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Compl 0.592 neurodegeneration test
Gamma Entrainment Synergy: HBOT-Enhanced Cerebral Perfusion 0.583 neurodegeneration View
LYTL and JIP4-dependent lysosomal remodeling may show mutant 0.580 neurodegeneration Do pathogenic LRRK2 mutations amplify vo
NLRP3 Inflammasome Blockade as Upstream Intervention to Prev 0.566 neurodegeneration Why have numerous phase 3 clinical trial
Timed Senolytic Therapy Eliminates p16^Ink4a/p21^Cip1-Senesc 0.564 neuroinflammation What molecular mechanisms drive the tran
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri 0.563 neurodegeneration Synaptic pruning by microglia in early A
Circadian-Gated Maresin Biosynthesis Amplification 0.557 neurodegeneration Neuroinflammation resolution mechanisms
Circulating hs-CRP as Disease-Modifying Target via Microglia 0.540 immunomics Systemic immune profiling in neurodegene

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (12)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
Single-cell RNA sequencing analysis of human atherosclerotic plaques exploratory Atherosclerosis 0.900 0.00 Human atherosclerotic plaque s proposed N/A
bEV isolation and LPS quantification from human samples clinical Alzheimer's disease 0.800 0.00 human patients proposed N/A
Proposed experiment from debate on Synaptic pruning by microglia in ea falsification Alzheimer's Disease 0.400 0.50 mouse proposed $200,000
Proposed experiment from debate on Senolytics targeting p16/p21+ senes falsification Neurodegeneration 0.400 0.50 cell_line proposed $80,000
Biomechanical Impact Profiles and Chronic Traumatic Encephalopathy Phe clinical Neurodegeneration 0.400 0.50 in_silico proposed $180,000
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%? clinical Alzheimer's Disease 0.400 0.50 human proposed $7,500,000
Experiment: Autoimmune Hypothesis Testing in AD clinical Alzheimer's Disease 0.400 0.50 human proposed $5,460,000
Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxic clinical Alzheimer's Disease 0.400 0.50 human proposed $5,460,000
cGAS-STING Pathway Validation Study in Parkinson's Disease clinical Parkinson's Disease 0.400 0.50 human proposed $7,100,000
Microglial Aging and Immune Memory in Neurodegeneration — Training the validation Alzheimer's Disease 0.400 0.50 human proposed $2,960,000
Microglial Contributions to Huntington's Disease Pathogenesis validation Neuroinflammation 0.400 0.50 human proposed $2,960,000
Mixed Pathology Effects on Parkinson's Disease Progression and Treatme clinical Alzheimer's Disease 0.400 0.50 human proposed $5,460,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Complement, Inflammasome, and Microglial Crosstalk in Glaucoma: From Neurodegene [PMID:41900887] Chen TY, Wu N, Sun X Life (Basel) 2026 1
Systemic Neurodegeneration and Brain Aging: Multi-Omics Disintegration, Proteost [PMID:40868276] Voicu V, Toader C, Șerban M, Covache-Bus Biomedicines 2025 1
Complement C1q/C3-CR3 signaling pathway mediates abnormal microglial phagocytosi [PMID:38642614] Han QQ, Shen SY, Liang LF, Chen XR, Yu J Brain Behav Immun 2024 1
Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. [PMID:37384704] Zhang T, Xu D, Trefts E, Lv M, Inuzuka H Science 2023 1
Microglia regulation of synaptic plasticity and learning and memory. [PMID:34472455] Cornell J, Salinas S, Huang HY, Zhou M Neural Regen Res 2022 1
Complement and microglia mediate early synapse loss in Alzheimer mouse models. [PMID:27033548] Hong S, Beja-Glasser VF, Nfonoyim BM, Fr Science 2016 1
Panacis Quinquefolii Radix Polysaccharides Alleviate Depressive-Like Behaviors i [PMID:41914021] Xie M, Feng L, Li R, Li M, Shen L, Zhang CNS neuroscience & therapeutic 2026 0
Vaccine-induced antibodies can limit Salmonella infection in the absence of comp [PMID:41738756] Perez-Toledo M, Aksu-Istil K, Marcial-Ju mBio 2026 0
The Immuno-Glial Connectome in Alzheimer's Disease: Integrating Central and Peri [PMID:41569436] Gopalakrishna PK, Che Mohd Nassir CMN, A Cellular and molecular neurobi 2026 0
Messengers of coagulopathy: complement-carrying extracellular vesicles in SARS-C [PMID:41766448] Taxiarchis A, Pruner I Current opinion in hematology 2026 0
Alzheimer's Disease as a Disorder of Neuroimmune Dysregulation. [PMID:41745721] Aranda-Abreu GE, Rojas-Durán F, Hernánde Neurology international 2026 0
The cholesterol 24-hydroxylase CYP46A1 promotes α-synuclein pathology in Parkins [PMID:39964974] Dai L, Wang J, Meng L, Zhang X, Xiao T, PLoS biology 2025 0
PDE4 inhibition alleviates HMGB1/C1q/C3-mediated excessive phagocytic pruning of [PMID:39947489] Zhao Q, Zeng C, Luo F, Xian Z, Wen H, Tu Brain, behavior, and immunity 2025 0
Botulinum Neurotoxin Induces Neurotoxic Microglia Mediated by Exogenous Inflamma [PMID:38342616] Ambrin G, Kang YJ, Van Do K, Lee C, Sing Advanced science (Weinheim, Ba 2024 0
Development of Injectable Thermosensitive Nanocomposite Hydrogel for Ratiometric [PMID:38456789] ["Zhu J", "Wei R", "Hu G", "Wang H", "Wa Small (Weinheim an der Bergstr 2024 0
The Role of Complement Dysregulation in Glaucoma. [PMID:38396986] ["Hoppe C", "Gregory-Ksander M"] International journal of molec 2024 0
Retracted: Ginsenoside Rg1 Ameliorates Acute Renal Ischemia/Reperfusion Injury v [PMID:38234567] ["Longevity O"] Oxidative medicine and cellula 2024 0
Divergent complement system activation in two clinically distinct murine models [PMID:35958570] ["Linzey M", "DiSano K", "Welsh N", "Pac Frontiers in immunology 2022 0
ATAD3A oligomerization promotes neuropathology and cognitive deficits in Alzheim [PMID:35236834] Zhao Y, Hu D, Wang R, Sun X, Ropelewski Nature communications 2022 0
Impact of satellite blood culture on early diagnosis of sepsis. [PMID:36789234] ["Guo Z", "Guo B", "Wang S", "Zhang H", Journal of intensive medicine 2022 0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning LIF in their description or question text

LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability in Diseas

Score: 0.770 · Alzheimer's Disease · 2026-04-05

## Mechanistic Overview LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability in Disease-Associated Mic

PARP1-NAD+-AIF bioenergetic collapse drives a self-amplifying parthanatos loop

Score: 0.760 · neurodegeneration · 2026-04-25

Oxidative DNA damage hyperactivates PARP1, rapidly consuming NAD+ and collapsing ATP production. Bioenergetic failure im

Selective blockade of classical-pathway activation downstream of C1q will reduce

Score: 0.750 · neurodegeneration · 2026-04-25

The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway

Iron-driven lipid peroxidation and GPX4 failure create a ferroptotic amplificati

Score: 0.750 · neurodegeneration · 2026-04-25

Labile Fe2+ converts H2O2 into hydroxyl radicals, driving phospholipid peroxidation that consumes GSH and disables GPX4-

Complement-SASP Amplification Cascade as Mechanistic Link

Score: 0.741 · neurodegeneration · 2026-04-16

**Molecular Mechanism and Rationale** The complement-SASP amplification cascade represents a mechanistic nexus where ce

Mutant-dependent amplification is context-dependent and strongest in microglia a

Score: 0.740 · neurodegeneration · 2026-04-24

A credible refinement is that any true amplification is not universal across cell types, but emerges most strongly in pr

TBK1 Loss-of-Function Amplifies C1q-Mediated Synapse Elimination Through Type I

Score: 0.724 · neurodegeneration · 2026-04-13

**Molecular Mechanism and Rationale** The molecular cascade underlying TBK1 loss-of-function-mediated synapse eliminati

Microglial IFN-β Priming of Motor Neuron cGAS/STING Amplification

Score: 0.720 · neurodegeneration · 2026-04-21

## **Molecular Mechanism and Rationale** The pathogenesis of amyotrophic lateral sclerosis (ALS) involves a complex int

Dual-Circuit Tau Vulnerability Cascade with Glial-Mediated Amplification

Score: 0.696 · neuroscience · 2026-04-07

## **Molecular Mechanism and Rationale** The dual-circuit tau vulnerability cascade with glial-mediated amplification r

Drp1-S616 Phosphorylation Fission Priming Enables t-Bid-Driven MPTP Amplificatio

Score: 0.693 · neurodegeneration · 2026-04-21

## Mechanistic Overview Drp1-S616 Phosphorylation Fission Priming Enables t-Bid-Driven MPTP Amplification starts from th

Glial Neuroinflammatory Amplification by TDP-43 Pathology

Score: 0.680 · neurodegeneration · 2026-04-21

## Mechanistic Overview Glial Neuroinflammatory Amplification by TDP-43 Pathology starts from the claim that modulating

LPS-primed microglial trained immunity establishes persistent H3K4me3 landscapes

Score: 0.670 · neurodegeneration · 2026-04-22

**Molecular Mechanism and Rationale** The molecular foundation of this hypothesis centers on the concept of trained imm

Heat Shock Protein 70 Disaggregase Amplification

Score: 0.668 · neurodegeneration · 2026-04-02

## Molecular Mechanism and Rationale The HSP70 chaperone system operates as a protein disaggregation machine through an

TREM2 Activation as an Amplification Node for R136S Protection

Score: 0.657 · neurodegeneration · 2026-04-13

## Mechanistic Overview TREM2 Activation as an Amplification Node for R136S Protection starts from the claim that modula

TREM2 Antagonism in Late-Stage Tauopathy — Reducing Neuroinflammatory Amplificat

Score: 0.628 · Alzheimer's disease · 2026-04-04

## Mechanistic Overview TREM2 Antagonism in Late-Stage Tauopathy — Reducing Neuroinflammatory Amplification starts from